Metronomic chemotherapy and immunotherapy in cancer treatment. (1st August 2017)

• Record Type: Journal Article
• Authors: Chen, Yu-Li; Chang, Ming-Cheng; Cheng, Wen-Fang
• Is Part Of: Cancer letters. Volume 400(2017)
• Page Start: 282
• Page End: 292
• Publication Date: 2017-08-01
• Subjects: Metronomic chemotherapy -- Immunotherapy -- Cancer therapy; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2017.01.040
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Systemic chemotherapy given at maximum tolerated doses (MTD) has been the mainstay of cancer treatment for more than half a century. In some chemosensitive diseases such as hematologic malignancies and solid tumors, MTD has led to complete remission and even cure. The combination of maintenance therapy and standard MTD also can generate good disease control; however, resistance to chemotherapy and disease metastasis still remain major obstacles to successful cancer treatment in the majority of advanced tumors. Metronomic chemotherapy, defined as frequent administration of chemotherapeutic agents at a non-toxic dose without extended rest periods, was originally designed to overcome drug resistance by shifting the therapeutic target from tumor cells to tumor endothelial cells. Metronomic chemotherapy also exerts anti-tumor effects on the immune system (immunomodulation) and tumor cells. The goal of immunotherapy is to enhance host anti-tumor immunities. Adding immunomodulators such as metronomic chemotherapy to immunotherapy can improve the clinical outcomes in a synergistic manner. Here, we review the anti-tumor mechanisms of metronomic chemotherapy and the preliminary research addressing the combination of immunotherapy and metronomic chemotherapy for cancer treatment in animal models and in clinical setting. Highlights: Metronomic chemotherapy is frequent, regular administration of drugs at non-toxic doses significantly below the MTD. Metronomic chemotherapy maintains low, but active concentrations of drugs over a long period, without serious toxicities. Metronomic chemotherapy is an antiangiogenic and a multi-targeted therapy with immunological properties. Metronomic chemotherapy with immunotherapy may enhance anti-tumor effects.